Hemolytic anemia is a condition in which red blood cells are destroyed faster than your body can replace them. Normally, red blood cells live about 120 days before the body recycles them. In hemolytic anemia, that lifespan is cut short, sometimes dramatically, leaving you without enough healthy cells to carry oxygen to your tissues. The condition can be mild and barely noticeable or severe enough to require emergency care, depending on the cause and how quickly the destruction happens.
How Red Blood Cells Get Destroyed
Red blood cells are remarkably flexible. They squeeze through blood vessels narrower than their own diameter, bending and rebounding thousands of times a day. When something goes wrong with their shape, surface proteins, or internal chemistry, they lose that flexibility and become targets for destruction.
Most hemolytic anemia involves one of two processes. In the more common form, the spleen filters out abnormal red blood cells. When a red blood cell can’t change shape well enough to pass through the spleen’s narrow passages, it gets trapped and broken down by immune cells. This is called extravascular hemolysis, and it’s the primary mechanism in conditions like sickle cell disease. In the less common form, called intravascular hemolysis, red blood cells rupture directly inside your blood vessels, spilling their contents into the bloodstream. This type tends to cause more dramatic symptoms and can damage the kidneys over time through iron deposits.
Inherited vs. Acquired Causes
Hemolytic anemia falls into two broad categories based on whether you’re born with the condition or develop it later in life.
Inherited Causes
Some people inherit genes that produce defective red blood cells from birth. The two most common inherited forms are sickle cell anemia, where red blood cells become rigid and crescent-shaped, and thalassemia, where the body makes abnormal hemoglobin. Both result in red blood cells that don’t survive as long as they should. Other inherited causes include enzyme deficiencies (like G6PD deficiency, which makes cells vulnerable to oxidative damage) and structural defects in the red blood cell membrane, such as hereditary spherocytosis, where cells are round and stiff instead of disc-shaped.
Acquired Causes
In acquired hemolytic anemia, you’re born with normal red blood cells, but something later causes them to be destroyed prematurely. Common triggers include:
- Autoimmune disorders such as lupus, rheumatoid arthritis, or ulcerative colitis, where the immune system mistakenly attacks red blood cells
- Infections, both viral and bacterial
- Medications, including certain antibiotics, antimalarials, and sulfa drugs
- Mechanical heart valves, which can physically shear red blood cells as blood flows through them
- Blood cancers and certain tumors
- An overactive spleen that filters out healthy cells along with damaged ones
- Severe transfusion reactions, where the body attacks donated blood cells
Autoimmune hemolytic anemia (AIHA) is one of the more common acquired forms, with an estimated incidence of roughly 2 to 7 new cases per 100,000 adults per year in the United States.
Warm vs. Cold Autoimmune Types
Autoimmune hemolytic anemia comes in two main subtypes, and the distinction matters because treatment differs significantly. In the warm type, which is more common, the immune system produces antibodies that attach to red blood cells at normal body temperature. These tagged cells are then eaten by immune cells in the spleen. In the cold type, the antibodies only bind to red blood cells at cooler temperatures, typically at or below room temperature. This means symptoms often flare in cold weather or when your extremities get chilled, because the antibodies activate in the cooler blood of your fingers, toes, and nose before triggering a chain reaction involving the complement system.
For warm autoimmune hemolytic anemia, treatment focuses on suppressing the immune response. For the cold type, keeping the body warm is a foundational part of management, alongside therapies that target the specific part of the immune cascade involved.
What Hemolytic Anemia Feels Like
The symptoms of hemolytic anemia come from two things happening at once: you’re losing red blood cells, and the breakdown products of those cells are building up in your body.
The anemia itself causes fatigue, weakness, shortness of breath, dizziness, and a fast heartbeat, especially during physical activity. These symptoms can develop gradually in chronic cases or hit suddenly if red blood cells are being destroyed rapidly.
The breakdown products cause a distinct set of signs. When red blood cells are destroyed, they release hemoglobin, which the body converts to bilirubin, a yellowish pigment. This excess bilirubin turns the skin and whites of the eyes yellow, a condition known as jaundice. Your urine may turn dark or cola-colored, particularly first thing in the morning, because the kidneys filter out some of the hemoglobin and its byproducts. The spleen often enlarges because it’s working overtime to clear damaged cells, and you may feel fullness or discomfort in the upper left side of your abdomen. Mild liver enlargement can also occur.
How It’s Diagnosed
Diagnosing hemolytic anemia involves confirming that red blood cells are being destroyed at an abnormal rate and then figuring out why. Doctors rely on a combination of blood tests that each reveal a different piece of the puzzle.
Haptoglobin is a protein that binds to free hemoglobin released from broken red blood cells. When hemolysis is happening, haptoglobin gets used up faster than the liver can make it, so blood levels drop. A level below 25 mg/dL has an 87% probability of indicating hemolytic disease. Lactate dehydrogenase (LDH), an enzyme released when cells are damaged, rises during hemolysis, with levels often reaching around 500 U/L and sometimes climbing much higher in severe cases. Bilirubin levels rise to roughly 2 to 3 mg/dL as the body processes the contents of destroyed red blood cells. Meanwhile, the reticulocyte count, which measures immature red blood cells freshly released from the bone marrow, climbs above 2.5%, reflecting the body’s attempt to compensate by producing replacements faster.
To determine whether the immune system is responsible, doctors use the direct antiglobulin test, often called the Coombs test. This test washes a blood sample to isolate your red blood cells, then adds a reagent that detects antibodies or immune proteins stuck to their surface. A positive result indicates that your immune system is targeting your own red blood cells, pointing toward autoimmune hemolytic anemia. A negative result suggests the destruction has a non-immune cause, such as a genetic defect or mechanical damage.
Long-Term Complications
Chronic hemolytic anemia puts ongoing stress on several organ systems. One of the most common complications is pigment gallstones. The constant breakdown of red blood cells produces excess bilirubin, which gets excreted into bile. Over time, this bilirubin can precipitate as calcium bilirubinate, forming hard black stones in the gallbladder. People with chronic hemolytic conditions like sickle cell disease or thalassemia develop gallstones at much higher rates and at younger ages than the general population.
Iron overload is another concern, particularly for people who need repeated blood transfusions to manage severe anemia. Each unit of transfused blood adds iron that the body has no efficient way to excrete, and that iron gradually accumulates in the liver, heart, and other organs. In cases of intravascular hemolysis, iron deposits in the kidneys can impair kidney function over time.
Treatment Approaches
Treatment depends entirely on the cause. For inherited forms, management focuses on preventing crises, supporting red blood cell production, and treating complications as they arise. Sickle cell disease and thalassemia each have their own specialized treatment pathways.
For autoimmune hemolytic anemia, the standard first-line treatment uses corticosteroids to suppress the immune attack on red blood cells, sometimes combined with intravenous immunoglobulin. Blood transfusions are given when anemia becomes severe enough to compromise organ function. Because severe hemolysis increases the risk of blood clots, preventive anticoagulation is often part of the treatment plan.
If the condition relapses or doesn’t respond to steroids, a targeted therapy called rituximab, which depletes the immune cells producing the harmful antibodies, has become the preferred second-line option. It has largely replaced splenectomy (surgical removal of the spleen), which was once the standard next step. Spleen removal is now typically reserved for cases that fail multiple other treatments. Dozens of newer therapies targeting different parts of the immune response are currently in development for patients who don’t respond to existing options.
For drug-induced hemolytic anemia, stopping the offending medication is usually enough. For cases caused by infections, treating the underlying infection allows the hemolysis to resolve. Mechanical causes, like a malfunctioning prosthetic heart valve, may require surgical correction.
Acute Hemolytic Crisis
When red blood cell destruction happens rapidly, it can become a medical emergency. An acute hemolytic crisis can cause a sudden, dangerous drop in hemoglobin, leading to severe shortness of breath, rapid heart rate, low blood pressure, and confusion. The priority in this situation is stabilizing you with fluids and, if needed, carefully matched blood transfusions while doctors work to identify the trigger. Some causes of acute hemolysis require very specific management. In certain conditions, for example, platelet transfusions must be avoided early on because they can worsen the underlying problem. Getting the right specialist involved quickly matters.